Premium
Practical blood dendritic cell vaccination for immunotherapy of multiple myeloma
Author(s) -
Vari F.,
Munster D. J.,
Hsu J. L.,
Rossetti T. R.,
Mahler S. M.,
Gray P. P.,
Turtle C. J.,
Prue R. L.,
Hart D. N. J.
Publication year - 2008
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2008.07346.x
Subject(s) - monoclonal antibody , multiple myeloma , peripheral blood mononuclear cell , medicine , immunotherapy , ctl* , vaccination , antigen , dendritic cell , cytotoxic t cell , immunology , antibody , t cell , immune system , chemistry , in vitro , cd8 , biochemistry
Summary Therapeutic vaccination combined with new drugs may cure multiple myeloma (MM). We have developed a bio‐process to purify CMRF‐56 monoclonal antibody (mAb) and a standard operating procedure to immunoselect blood dendritic cells (BDC). Leucopheresed mononuclear cells were cultured overnight, labelled with CMRF‐56 mAb and BDC prepared using a clinical scale immunoselection system. The mean BDC yield from healthy donors was 48% ( n = 6, purity 28%). Preparations from MM patients ( n = 6, yield 47%, purity 35%) primed cytotoxic T lymphocytes (CTL) to clinically relevant MM antigens. This procedure can be performed readily by clinical cell manufacturing units to facilitate BDC vaccination studies.